The landscape of therapies for multiple sclerosis (MS) is constantly shifting. Currently, there are 11 FDA approved agents for chronic disease treatment, multiple drugs in clinical trials for acute and chronic disease management and numerous compounds used for symptom control. Beyond treating patients who may be on these medications and in some cases prescribing these medications, neuroophthalmologists may be the evaluating physician for specific complications with neuro-ophthalmic symptoms and signs. Thus it is critically important that neuroophthalmologists stay abreast of new and emerging MS medications.
Date
2017-04-05
Language
eng
Format
video/mp4
Source
2017 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of
NANOS Annual Meeting 2017: Neuro-Ophthalmologic Side Effects of More Recently Used Medications in Treating Cancer, Rheumatologic Disorders, and Multiple Sclerosis
